Answer
Pegaspargase (Oncaspar) may increase glucocorticoid-induced osteonecrosis risk in children and adolescents when both treatments are given simultaneously, with higher incidence in girls, potentially through increased dexamethasone exposure.
Sources for this answer
- Oncaspar 750 U/ml powder for solution for injection/infusionServier Laboratories Limited · emc · SmPC §4.5 Interaction with other medicinal products · Version 8Document updated
Sources checked